Replies to post #23935 on BioSante Pharmaceuticals, Inc. (BPAX)

[rgshredder]

agree with you 100%
1mil is chump change, just hoping the royalties compensate for the buy in. Hey, it's 1 more million closer to 49.9%.
-RG

[Just the facts maam]

Jadite, I believe you are correct on the sheltering of GVAX. Do you think having Dr Drew Pardoll (Board Observer) didn't way in their decision to sell to Aduro. He invented GVAX vaccines and is pretty well connected to the Cancer program at Sydney Kimmel comprehensive center.

Dr. Pardoll

Dr. Pardoll is Seraph Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University of Medicine. He is Co-Director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center. Dr. Pardoll completed his M.D., Ph.D., Medical Residency and Oncology Fellowship at Johns Hopkins University. Dr. Pardoll has published over 200 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, Cell Genesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma-delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines.